Difficulty: Medium
Average Score: 65%
Practice
Concerning the drugs used in parkinsonism, which of the following statements is accurate?
Correct answer
B
Rationale
The correct answer is B) The concomitant use of selegiline may increase the peripheral adverse effects of levodopa.
Explanation:
Selegiline is a selective irreversible MAO-B inhibitor commonly used in the treatment of Parkinson's disease. When used with levodopa, selegiline can potentiate the peripheral side effects of levodopa, such as nausea, vomiting, and orthostatic hypotension. This interaction is important to note in clinical practice to avoid exacerbating these adverse effects in patients with Parkinson's disease.
Why the other options are wrong:
A) Levodopa does not cause mydriasis or precipitate an attack of acute glaucoma. These are not known side effects of levodopa.
C) Antimuscarinic drugs are used in Parkinson's disease to help control tremors and rigidity, not primarily for relieving bradykinesia.
D) Dopamine receptor agonists can be used as initial monotherapy in Parkinson's disease without the need for a trial of levodopa. They are often considered as first-line therapy in younger patients to delay the onset of motor complications associated with levodopa use.
Educational context:
Understanding the pharmacological management of Parkinson's disease is crucial for healthcare professionals involved in the care of patients with this condition. Knowing the interactions between different drugs used in Parkinsonism is essential to optimize treatment outcomes and minimize adverse effects. This question highlights the importance of considering drug interactions when managing patients with Parkinson's disease.
Explanation:
Selegiline is a selective irreversible MAO-B inhibitor commonly used in the treatment of Parkinson's disease. When used with levodopa, selegiline can potentiate the peripheral side effects of levodopa, such as nausea, vomiting, and orthostatic hypotension. This interaction is important to note in clinical practice to avoid exacerbating these adverse effects in patients with Parkinson's disease.
Why the other options are wrong:
A) Levodopa does not cause mydriasis or precipitate an attack of acute glaucoma. These are not known side effects of levodopa.
C) Antimuscarinic drugs are used in Parkinson's disease to help control tremors and rigidity, not primarily for relieving bradykinesia.
D) Dopamine receptor agonists can be used as initial monotherapy in Parkinson's disease without the need for a trial of levodopa. They are often considered as first-line therapy in younger patients to delay the onset of motor complications associated with levodopa use.
Educational context:
Understanding the pharmacological management of Parkinson's disease is crucial for healthcare professionals involved in the care of patients with this condition. Knowing the interactions between different drugs used in Parkinsonism is essential to optimize treatment outcomes and minimize adverse effects. This question highlights the importance of considering drug interactions when managing patients with Parkinson's disease.